How Cell And Gene Therapies Are Evolving

Cell and gene therapy are emerging as promising treatments, especially in oncology. These therapies involve modifying immune cells to target specific cancer cells. Chimeric antigen receptor (CAR) T-cell therapies have seen rapid growth, with multiple therapies approved by regulatory bodies. However, there's a supply and demand imbalance, particularly for cancer-targeting cell therapies, and the high cost of commercial cell therapy limits patient access. Advances in manufacturing technologies and equipment are improving the efficiency and reproducibility of these therapies, potentially reducing costs and increasing accessibility.

The cell and gene therapy manufacturing supply chain is evolving, with a focus on reducing costs and making these therapies more affordable and widely available. Thousands of therapies are currently in clinical trials, with potential to provide effective treatments for various diseases and conditions. The use of induced pluripotent stem cells (IPSCs), which can become any cell type, is also of interest. Streamlining regulatory approval pathways and increasing the use of artificial intelligence (AI) in the market could unlock potential and value in the industry.